We studied 193 Enterobacteriaceae isolates presenting diminished susceptibility to oxyimino-cephalosporins recovered in a Portuguese hospital (2004)(2005)(2006)(2007)(2008). CTX-M-3 producers, firstly detected in Portugal, were associated with a Klebsiella pneumoniae microepidemic clone. Production of CTX-M-type enzymes (CTX-M-1/-3/-9/-14/-15/-32), age ≥65 years, and nosocomial infection were risk factors for higher nonsusceptibility to oxyimino-β-lactams. CMY-2 and DHA-1 β-lactamases were only identified in 1% of isolates.
as well as its association with ESBL production; this is presented here for 1 hospital providing diverse health care facilities. The newly detected CTX-M-3 variant in Portugal is also reported.
Between the first semesters of 2004 to 2008, 193 Enterobacteriaceae (109 Escherichia coli, 81 Klebsiella pneumoniae and 3 Proteus mirabilis) isolates were collected consecutively (1 per patient), at Hospital Garcia de Orta, in Portugal and identified as ESBL producers. It is a 600-bed tertiary-level hospital (including a 28-bed intensive care unit), with a catchment population of about 390,000 citizens. Nosocomial (107/193, 55 .4%) or community-acquired infections (75/193, 38.9%) were identified according to Centers of Disease Control and Prevention criteria (Garner et al., 1988) ; 11 (5.7%) of 193 were of unknown origin. The isolates were reached from different biological samples: urine (127, 65.8%), blood (27, 14.0%), wounds (17, 8.8%) , others (18, 9.3%), and unknown origin (4, 2.1%).
Among all isolates, 106 (54.9%) were from women and 84 (43.5%) from men: 120 (62.2%) from patients ≥65 years old, 41 (21.2%) from patients 41-64 years old, 21 (10.9%) from patients 19-40 years old, and 8 (4.1%) from ≤18 years Table 1 Antimicrobial susceptibility of the 193 Enterobacteriaceae ESBL-, non-ESBL-, and PMAβ-producing isolates 
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Amoxicillin (25) Disk diffusion method and MICs were used to test the antimicrobial susceptibility of clinical isolates, and transformants plus their clinical isolates, respectively (SFM; http:// www.sfm-microbiologie.org/) (Tables 1 and 2 ). All Enterobacteriaceae presented diminished susceptibility to at least 1 oxyimino-cephalosporin and 88.1% to aztreonam. In this set of strains, 69.4% (134/193) were multidrug-resistant (MDR), as presenting a reduced susceptibility to 3 or more structurally unrelated antibiotics, among which were fluoroquinolones (97%), aminoglycosides (91.8%), and trimethoprim-sulfamethoxazole (72.4%). Clinical isolates were tested for the presence of bla ESBL and bla PMAβ genes, by using polymerase chain reaction and sequencing, as described previously (Mendonça et al., 2009; Pérez-Pérez and Hanson, 2002) . Overall, the presence of ESBLs was confirmed in 167 of 193 isolates and the bla CTX-M genes in 154 of 167 isolates (CTX-M-ESBL group), such as bla CTX-M-1 (6, 3.9%), bla CTX-M-3 (13, 8.4%), bla CTX-M-9 (2, 1.3%), bla CTX-M-14 (4, 2.6%), bla CTX-M-15 (123, 79.9%), and bla CTX-M-32 (6, 3.9%). Among the CTX-M group, 76.0% of isolates were MDR, 62.4% of them with a nosocomial origin, which is a cause of concern (Pitout et al., 2005) . Two bla CMY-2 genes were identified in E. coli isolates in association with bla CTX-M-15 gene (Table 1) . Indeed, as reported in Taiwan (Chen et al., 2007) , the coexistence of ESBL and AmpC β-lactamases not only limits treatment options, but also complicates routine phenotypic detection of ESBLs, causing a growing problem for clinical microbiology laboratories (Hanson, 2003; Pai et al., 2004) .
In the non-CTX-M-ESBL group (n = 13), we detected β-lactamase genes of the SHV (bla SHV-2a , n = 3; bla SHV-12 , n = 7; bla SHV-115 , n = 1), TEM (bla TEM-10 , n = 1; bla TEM-52 , n = 1; bla TEM-107 , n = 1), and GES (bla GES-1 , n = 1) families, alone or associated with each other, with non-ESBL genes (bla , bla TEM-1 and bla OXA-30 ) or with inhibitor-resistant SHV genes (bla ). Two non-ESBL PMAβ-producing isolates were identified: 1 E. coli expressing the bla CMY-2 gene and 1 K. pneumoniae expressing the bla DHA-1-type gene. PMAβ-producing isolates were nonsusceptible to almost all β-lactams tested, except the combination of piperacillin plus tazobactam, cefepime, ceftriaxone, and carbapenems (Table 1) . No ESBL enzymes of the CTX-M family were detected in 1999 in this hospital, in contrast with the identification of a CMY-2-typeproducing isolate (data not shown). However, here, there was a substantial emergence in the number of ESBLs found. Although ESBLs from SHV, TEM, and GES families are important, because they confer β-lactamase-mediated resistance to oxyimino-β-lactams on Enterobacteriaceae, the ability of CTX-M enzymes to spread between different pathogens has led to it becoming the most significant problem (Cantón and Coque, 2006; Hawkey and Jones, 2009; Livermore et al., 2007) .
Conjugation, performed by liquid and solid mating assays , showed that all CTX-Mtype determinants tested were found to be carried on conjugative plasmids, facilitating their spread (Cantón and Coque, 2006) . In general, the transformants had antibiotic resistance profiles similar to those of their parental clinical isolates (Table 2) .
We tested for risk factors associated with nonsusceptibility to oxyimino-β-lactams, mediated by the production of β-lactamases, in Enterobacteriaceae isolates (Table 3; only factors identified as significant are shown: P ≤ 0.05). OpenEpi software, version 2.3.1 (Sullivan et al., 2009) , was used for statistical analysis. Fisher exact test was used to assess differences in antibiotic resistance between different groups. Two-sided P values of ≤0.05 were considered to be statistically significant. Associations were determined by calculation of odds ratios with 95% confidence intervals. The null hypothesis was rejected for P values of ≤0.05. Higher nonsusceptibility rates were consistently associated (for at least 4 of the 6 classes of antibiotics tested and MDR) with an age of ≥65 years, nosocomial infection, and production of CTX-M-type enzymes (Table 3) . Long-term hospitalizations leading to nosocomial infections and exposure to antibiotics have also been described by others as risk factors for the acquisition of ESBL-producing isolates (Ben-Ami et al., 2009; Lavigne et al., 2007) . A protective association was found for other age groups than ≥65 years, for the acquisition of infections due to non-ESBL-producing isolates and for the community-acquired infections. The internal medicine ward was a risk factor for nonsusceptibility to oxyimino-β-lactams and surgery for nonsusceptibility to trimethoprim-sulfamethoxazole. Enterobacteriaceae isolates collected from urine were significantly associated with nonsusceptibility to fluoroquinolones, but not to the other drugs tested. We also found that nonsusceptibility to oxyimino-β-lactams, aminoglycosides, and quinolones was associated with CTX-M-ESBL isolates, and this may be related to the dissemination of a single plasmid or to other mobile genetic elements (Cantón and Coque, 2006; Nicolas-Chanoine et al., 2008; Woodford et al., 2009 ).
The clonal relationship between 49 E. coli and K. pneumoniae isolates representative of all CTX-M β-lactamase groups, years, community/nosocomial origin, and wards was studied by pulsed-field gel electrophoresis as previously described (Mendonça et al., 2007) (Fig. 1) . The persistent E. coli CTX-M-15-producer clone (cluster EcII) was widespread across diverse hospital wards and over several years. K. pneumoniae-producing CTX-M-15 (cluster KpI) and CTX-M-3 (cluster KpII) were mostly isolated in internal medicine and included both nosocomial and communityacquired isolates (Fig. 1) . Clonality suggests that a microepidemic clone emerged in this hospital in 2006, in both pathogens, and disappeared in 2008, revealing the first description of CTX-M-3 in Portugal, an enzyme initially reported in 1995 in Citrobacter freundii and in E. coli isolates from Poland (Gniadkowski et al., 1998) . Other outbreaks associated with Gram-negative isolates producing CTX-M-3 have been described all over the world (Dutour et al., 2002; Empel et al., 2008; Literacka et al., 2009; Moriguchi et al., 2007; Ramdani-Bouguessa et al., 2006; Yan et al., 2000) .
Given the spread of both CTX-M-3 and CTX-M-15 β-lactamases in this hospital and the recent demonstration that CTX-M-3 variants (such as CTX-M-15) confer greater resistance to extended-spectrum cephalosporins (Novais et al., 2010) , monitoring isolates for the presence and evolution of bla ESBL , and particularly bla CTX-M , is now imperative.
